OBJECTIVES: Over-expression of the proto-oncogene c-erbB-2 (HER-2 ⁄ neu) has been shown to be a prognostic marker in many kinds of cancer, whereas conflicting data exist about the prevalence of HER-2 ⁄ neu over-expression in squamous cell carcinoma (SCC) of the tongue. The status of Her-2 ⁄ neu was evaluated in a series of SCC of the tongue to verify the frequency of over-expression of HER-2 ⁄ neu and evaluate the correlation with traditional diagnostic parameters of this neoplasm. METHOD: Fourty patients with SCC of the tongue were investigated for over-expression of the protein through immunohistochemistry using CB11 antibody, the Hercep Test kit and FISH. RESULTS: Data obtained using the Hercep Test differ from published reports concerning the over-expression of Her-2 ⁄ neu and there was no correlation between levels of expression of Her-2 ⁄ neu and other clinico-pathological and ⁄ or prognostic parameters. Of the 40 specimens, using CB11 we obtained results in line with published reports; however, with the Hercep Test we found only 1 positive case (2.5%) (score 3+). CONCLUSION: These data, confirmed by FISH, suggest that Her-2 ⁄ neu is not a suitable marker that could play a primary role in the clinical-therapeutic management of SCC of the tongue. J Oral Pathol Med (2008) 37: 145–150
HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance.
DESSY, Enrico;
2010-01-01
Abstract
OBJECTIVES: Over-expression of the proto-oncogene c-erbB-2 (HER-2 ⁄ neu) has been shown to be a prognostic marker in many kinds of cancer, whereas conflicting data exist about the prevalence of HER-2 ⁄ neu over-expression in squamous cell carcinoma (SCC) of the tongue. The status of Her-2 ⁄ neu was evaluated in a series of SCC of the tongue to verify the frequency of over-expression of HER-2 ⁄ neu and evaluate the correlation with traditional diagnostic parameters of this neoplasm. METHOD: Fourty patients with SCC of the tongue were investigated for over-expression of the protein through immunohistochemistry using CB11 antibody, the Hercep Test kit and FISH. RESULTS: Data obtained using the Hercep Test differ from published reports concerning the over-expression of Her-2 ⁄ neu and there was no correlation between levels of expression of Her-2 ⁄ neu and other clinico-pathological and ⁄ or prognostic parameters. Of the 40 specimens, using CB11 we obtained results in line with published reports; however, with the Hercep Test we found only 1 positive case (2.5%) (score 3+). CONCLUSION: These data, confirmed by FISH, suggest that Her-2 ⁄ neu is not a suitable marker that could play a primary role in the clinical-therapeutic management of SCC of the tongue. J Oral Pathol Med (2008) 37: 145–150File | Dimensione | Formato | |
---|---|---|---|
ANTICANCER RESEARCH 30 3435-3440 (2010).pdf
gestori archivio
Tipologia:
Full Text
Licenza:
DRM non definito
Dimensione
174.66 kB
Formato
Adobe PDF
|
174.66 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.